Editas Medicine Inc (EDIT)

09:41 AM

How high can Editas Medicine Inc. stock goJuly 2025 Catalysts & Weekly Chart Analysis and Guides - newser.com

09:41 AM

09:35 AM

Can Editas Medicine Inc. stock sustain institutional interest2025 Valuation Update & High Yield Stock Recommendations - newser.com

09:35 AM

09:32 AM

Why Editas Medicine Inc. stock is in analyst buy zoneWeekly Trade Analysis & Low Volatility Stock Recommendations - newser.com

09:32 AM

08:58 AM

Published on: 2025-10-13 07:58:32 - newser.com

08:58 AM

05:06 AM

Using flow based indicators on Editas Medicine Inc.2025 Momentum Check & Daily Stock Momentum Reports - newser.com

05:06 AM

Oct 12, 2025

Published on: 2025-10-12 10:38:16 - newser.com

Oct 12, 2025

Oct 11, 2025

What analysts say about Editas Medicine Inc stockShort Interest Overview & Grow Smarter With Pro-Level Research - earlytimes.in

Oct 11, 2025

Oct 10, 2025

Editas Medicine Hits New 52-Week High of $4.05, Marking Key Milestone - Markets Mojo

Oct 10, 2025

Oct 10, 2025

Editas Medicine Inc 8EM Stock Analysis and ForecastSwing Trading Ideas & Free High Return Strategy Alerts - earlytimes.in

Oct 10, 2025

Oct 10, 2025

How Editas Medicine Inc. (8EM) stock valuation compares with sectorGold Moves & Capital Efficiency Focused Strategies - newser.com

Oct 10, 2025

Oct 10, 2025

Leading vs lagging indicators on Editas Medicine Inc. performanceTrade Ideas & Technical Pattern Based Signals - newser.com

Oct 10, 2025

Oct 10, 2025

CRISPR Market Size, Share, Recent Developments, Growth - openPR.com

Oct 10, 2025

Oct 10, 2025

Regression analysis insights on Editas Medicine Inc. performanceQuarterly Earnings Report & High Conviction Buy Zone Alerts - newser.com

Oct 10, 2025

Oct 10, 2025

Is Editas Medicine Inc. (8EM) stock a top hedge fund pickBond Market & Low Drawdown Trading Strategies - newser.com

Oct 10, 2025

Oct 10, 2025

Editas Medicine (NASDAQ:EDIT) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat

Oct 10, 2025

Oct 09, 2025

Editas Medicine Unveils Promising Preclinical Data on EDIT-401 - TipRanks

Oct 09, 2025

Oct 09, 2025

Editas Medicine Hits New 52-Week High of $4.54, Marking Significant Milestone - Markets Mojo

Oct 09, 2025

Oct 09, 2025

Editas Medicine reports 90% LDL-C reduction in preclinical studies By Investing.com - Investing.com Nigeria

Oct 09, 2025

Oct 09, 2025

Editas Medicine reports 90% LDL-C reduction in preclinical studies - Investing.com India

Oct 09, 2025

Oct 09, 2025

Editas Medicine (EDIT) Showcases Promising Preclinical Data for LDL Reduction - GuruFocus

Oct 09, 2025

Oct 09, 2025

Editas Medicine Reports Promising Preclinical Data for LDL-Cholesterol-Lowering Gene Editing Therapy EDIT-401 at ESGCT Congress - Quiver Quantitative

Oct 09, 2025

Oct 09, 2025

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress - The Manila Times

Oct 09, 2025

Oct 09, 2025

Editas Medicine Reports In Vivo Proof-of-Concept Data for - GlobeNewswire

Oct 09, 2025

Oct 09, 2025

Editas Medicine reports 90% LDL cholesterol reduction in animal studies - StreetInsider

Oct 09, 2025

Oct 09, 2025

Editas Medicine Inc. stock retracement – recovery analysis2025 Trade Ideas & Weekly Top Performers Watchlists - newser.com

Oct 09, 2025

Oct 09, 2025

Best data tools to analyze Editas Medicine Inc. stockForecast Cut & Fast Entry High Yield Tips - newser.com

Oct 09, 2025

Oct 09, 2025

Historical volatility pattern of Editas Medicine Inc. visualizedFed Meeting & Target Return Focused Stock Picks - newser.com

Oct 09, 2025

Oct 09, 2025

How risky is Editas Medicine Inc. stock nowWeekly Investment Recap & Weekly Top Stock Performers List - newser.com

Oct 09, 2025

Oct 07, 2025

While institutions invested in Editas Medicine, Inc. (NASDAQ:EDIT) benefited from last week's 11% gain, individual investors stood to gain the most - Sahm

Oct 07, 2025

Oct 06, 2025

Editas Medicine to present CRISPR cholesterol research at ESGCT By Investing.com - Investing.com Nigeria

Oct 06, 2025

Oct 06, 2025

Editas Medicine to present CRISPR cholesterol research at ESGCT - Investing.com

Oct 06, 2025

Oct 06, 2025

Editas Medicine to Present Groundbreaking LDL-Cholesterol-Lowering CRISPR Gene Editing Research at ESGCT Congress 2025 - Quiver Quantitative

Oct 06, 2025

Oct 06, 2025

Editas Medicine Announces EDIT-401 Oral Presentation at the - GlobeNewswire

Oct 06, 2025

Oct 06, 2025

Editas Medicine to present EDIT-401 data at gene therapy congress - StreetInsider

Oct 06, 2025

Oct 06, 2025

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences - Yahoo Finance

Oct 06, 2025

Oct 06, 2025

How Editas Medicine Inc. (8EM) stock responds to job market shiftsEarnings Growth Report & Reliable Volume Spike Trade Alerts - newser.com

Oct 06, 2025

Oct 06, 2025

Real time alert setup for Editas Medicine Inc. performanceJuly 2025 Earnings & Capital Efficiency Focused Ideas - newser.com

Oct 06, 2025

Oct 06, 2025

Will Editas Medicine Inc. continue its uptrendForecast Cut & Expert Curated Trade Ideas - newser.com

Oct 06, 2025

Oct 06, 2025

Editas Medicine Hits New 52-Week High at $4.07, Marking Significant Milestone - Markets Mojo

Oct 06, 2025

Oct 05, 2025

Using data filters to optimize entry into Editas Medicine Inc.Trade Volume Summary & Precise Buy Zone Identification - newser.com

Oct 05, 2025

Oct 05, 2025

Is Editas Medicine Inc. (8EM) stock vulnerable to rate hikesEarnings Performance Report & Weekly Sector Rotation Insights - newser.com

Oct 05, 2025

Oct 05, 2025

Can Editas Medicine Inc. rally from current levelsPortfolio Profit Report & Real-Time Volume Trigger Notifications - newser.com

Oct 05, 2025

Oct 03, 2025

Editas Medicine Inc. stock trendline breakdownJuly 2025 Trends & Low Risk Growth Stock Ideas - newser.com

Oct 03, 2025

Oct 03, 2025

Price momentum metrics for Editas Medicine Inc. explainedWall Street Watch & Accurate Entry/Exit Alerts - newser.com

Oct 03, 2025